89th European Atherosclerosis Society Congress 2021
HEYMANS: Real-world use of evolocumab in familial hypercholesterolaemia
New insights from the HEYMANS study show that patients with familial hypercholesterolaemia (FH) are not optimally treated in real-world practice in Europe. The findings were reported at EAS Helsinki 2021 Virtual. The 2019 European Society of Cardiology (ESC)/EAS dyslipidaemia guidelines (1) emphasised the need for…
read more »
News from the EAS-led HICC registry
The homozygous familial hypercholesterolaemia International Clinical Collaboration (HICC) registry is the largest global database of homozygous familial hypercholesterolaemia (HoFH) patients (1). New data reported at EAS Helsinki 2021 Virtual show that patients in non-high-income countries are less likely to have access to novel treatments, including…
read more »
DA VINCI highlights inequity in treatment access in Europe
New findings from the DA VINCI study illustrate inequity in cholesterol management across Europe, especially in Central and Eastern European countries. The findings were reported at EAS Helsinki 2021 Virtual (1). DA VINCI was a cross-sectional, observational study in 5888 patients (3000 in primary prevention…
read more »
HAUSER-RCT: Evolocumab did not affect cognition in children with FH
HAUSER-RCT showed that monthly injections of evolocumab were efficacious in adding robust LDL cholesterol lowering on top of usual care in paediatric heterozygous familial hypercholesterolaemia (FH) patients (1). While the trial also showed a favourable safety profile, especially the lack of effect on growth rates,…
read more »
More news from the posters
First data from OMERO: real-world experience with alirocumab OMERO is a prospective study evaluating the long-term effectiveness, tolerability, and safety of alirocumab (on top of standard lipid lowering therapy) in real-world practice in Italy. This interim report provides data from 352 (out of 800) patients…
read more »
